{
    "title": "109_s1978",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as ``Tim Fagan's Law'' or the ``Counterfeit \nDrug Enforcement Act of 2005''.\n\nSEC. 2. SALE OR TRADE OF PRESCRIPTION DRUGS KNOWINGLY CAUSED TO BE \n              ADULTERATED OR MISBRANDED; MISREPRESENTATION AS APPROVED \n              DRUGS.\n\n    (a) Criminal Penalty.--Section 303(a) of the Federal Food, Drug, \nand Cosmetic Act (21 U.S.C. 333(a)) is amended by adding at the end the \nfollowing paragraphs:\n            ``(3) Notwithstanding paragraph (1) or (2), in the case of \n        a person who violates section 301(a), 301(b), or 301(c) with \n        respect to a drug that is subject to section 503(b)(1)(B), if \n        the person knowingly caused the drug to be adulterated or \n        misbranded and sells or trades the drug, or the person \n        purchases or trades for the drug knowing or having reason to \n        know that the drug was knowingly caused to be adulterated or \n        misbranded, the person shall be fined in accordance with title \n        18, United States Code, or imprisoned for any term of years or \n        for life, or both.\n            ``(4) Notwithstanding paragraph (1) or (2), in the case of \n        a person who violates section 301(d) with respect to a drug, if \n        the person caused the drug to be misrepresented as a drug that \n        is subject to section 503(b)(1)(B) and for which an approved \n        application is in effect under section 505 and the person sells \n        or trades the drug, or the person purchases or trades for the \n        drug knowing or having reason to know that the drug was \n        knowingly caused to be so misrepresented, the person shall be \n        fined in accordance with title 18, United States Code, or \n        imprisoned for any term of years or for life, or both.''.\n    (b) Notification of Food and Drug Administration by \nManufacturers.--Section 505(k) of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 355(k)) is amended by adding at the end the following \nparagraph:\n            ``(3) A manufacturer of a drug that receives or otherwise \n        becomes aware of information that reasonably suggests that a \n        violation described in paragraph (3) or (4) of section 303(a) \n        may have occurred with respect to the drug shall report such \n        information to the Secretary not later than 48 hours after \n        first receiving or otherwise becoming aware of the \n        information.''.\n\nSEC. 3. USE OF TECHNOLOGIES FOR PREVENTING COUNTERFEITING OF DRUGS.\n\n    Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n352) is amended by adding at the end the following:\n    ``(x) If it is a drug and it is not manufactured in accordance with \nany regulations of the Secretary requiring the use of technologies that \nthe Secretary has determined are technically feasible and will assist \nin preventing violations of this Act to which paragraphs (3) and (4) of \nsection 303(a) apply (relating to the knowing adulteration or \nmisbranding of drugs and the knowing misrepresentation of drugs).''.\n\nSEC. 4. WHOLESALE DISTRIBUTION OF DRUGS; STATEMENTS REGARDING PRIOR \n              SALE, PURCHASE, OR TRADE.\n\n    (a) Striking of Exemptions for Manufacturers and Authorized \nDistributors of Record.--Section 503(e) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 353(e)) is amended--\n            (1) in paragraph (1)--\n                    (A) by striking ``and who is not the manufacturer \n                or an authorized distributor of record of such drug'';\n                    (B) by striking ``to an authorized distributor of \n                record or''; and\n                    (C) by striking subparagraph (B) and inserting the \n                following:\n                    ``(B) The Secretary shall by regulation establish \n                requirements that supersede subparagraph (A) (referred \n                to in this subparagraph as `alternative requirements') \n                to identify the chain of custody of a drug subject to \n                subsection (b) from the manufacturer of the drug \n                throughout the wholesale distribution of the drug to a \n                pharmacist who intends to sell the drug at retail if \n                the Secretary determines that--\n                            ``(i) the alternative requirements, which \n                        may include standardized anti-counterfeiting or \n                        track-and-trace technologies, will identify \n                        such chain of custody or the identity of the \n                        discrete package of the drug from which the \n                        drug is dispensed with equal or greater \n                        certainty to the requirements of subparagraph \n                        (A); and\n                            ``(ii) the alternative requirements are \n                        economically and technically feasible.''; and\n            (2) in paragraph (3), by striking ``and subsection (d)--'' \n        in the matter preceding subparagraph (A) and all that follows \n        through ``the term `wholesale distribution' means'' in \n        subparagraph (B) and inserting the following: ``and subsection \n        (d), the term `wholesale distribution' means''.\n    (b) Conforming Amendment.--Section 503(d) of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 353(d)) is amended by adding at the \nend the following:\n            ``(4) Each manufacturer of a drug subject to subsection (b) \n        shall maintain at its corporate offices a current list of the \n        authorized distributors of record of such drug.\n            ``(5) For purposes of this subsection, the term `authorized \n        distributors of record' means any distributor that a \n        manufacturer designates as an authorized distributor of record \n        and whose name the manufacturer makes publicly available.''.\n    (c) Effective Date.--\n            (1) In general.--The amendments made by subsections (a) and \n        (b) shall take effect on January 1, 2010.\n            (2) High-risk drugs.--\n                    (A) In general.--Notwithstanding paragraph (1), the \n                Secretary of Health and Human Services (referred to in \n                this section as the ``Secretary'') may apply the \n                amendments made by subsections (a) and (b) before \n                January 1, 2010, with respect to a prescription drug if \n                the Secretary--\n                            (i) determines that the drug is at high \n                        risk for being counterfeited; and\n                            (ii) publishes the determination and the \n                        basis for the determination in the Federal \n                        Register.\n                    (B) Pedigree not required.--Notwithstanding a \n                determination under subparagraph (A) with respect to a \n                prescription drug, the amendments described in such \n                subparagraph shall not apply with respect to a \n                wholesale distribution of such drug if the drug is \n                distributed by the manufacturer of the drug to a person \n                that distributes the drug to a retail pharmacy for \n                distribution to the consumer or patient, with no other \n                intervening transactions.\n                    (C) Limitation.--The Secretary may make the \n                determination under subparagraph (A) with respect to \n                not more than 50 drugs before January 1, 2010.\n            (3) Alternative requirements.--The Secretary shall issue \n        regulations to establish the alternative requirements, referred \n        to in the amendment made by subsection (a)(1), that take effect \n        not later than--\n                    (A) January 1, 2008, with respect to a prescription \n                drug determined under paragraph (2)(A) to be at high \n                risk for being counterfeited; and\n                    (B) January 1, 2010, with respect to all other \n                prescription drugs.\n            (4) Intermediate requirements.--With respect to the \n        prescription drugs described under paragraph (3)(B), the \n        Secretary shall by regulation require the use of standardized \n        anti-counterfeiting or track-and-trace technologies on such \n        prescription drugs at the case and pallet level effective not \n        later than January 1, 2008.\n\nSEC. 5. COUNTERFEIT DRUGS; INCREASED FUNDING FOR INSPECTIONS, \n              EXAMINATIONS, AND INVESTIGATIONS.\n\n    For the purpose of increasing the capacity of the Food and Drug \nAdministration to conduct inspections, examinations, and investigations \nunder the Federal Food, Drug, and Cosmetic Act with respect to \nviolations described in paragraphs (3) and (4) of section 303(a) of \nsuch Act (as added by this Act), there is authorized to be appropriated \n$60,000,000 for each of the fiscal years 2006 through 2010, in addition \nto other authorizations of appropriations that are available for such \npurpose.\n\nSEC. 6. PUBLIC EDUCATION REGARDING COUNTERFEIT DRUGS.\n\n    (a) In General.--The Secretary of Health and Human Services shall \ncarry out a program to educate the public and health care professionals \non counterfeit drugs, including techniques to identify drugs as \ncounterfeit.\n    (b) Authorization of Appropriations.--For the purpose of carrying \nout subsection (a), there is authorized to be appropriated $5,000,000 \nfor each of the fiscal years 2006 through 2010, in addition to other \nauthorizations of appropriations that are available for such purpose.\n\nSEC. 7. RECALL AUTHORITY REGARDING DRUGS.\n\n    Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 351 et seq.) is amended by inserting after section 506C \nthe following:\n\n``SEC. 506D. RECALL AUTHORITY.\n\n    ``(a) Order To Cease Distribution of Drug; Notification of Health \nProfessionals.--\n            ``(1) In general.--If the Secretary finds that there is a \n        reasonable probability that a drug intended for human use would \n        cause serious, adverse health consequences or death, the \n        Secretary shall issue an order requiring the appropriate person \n        (including the manufacturers, importers, distributors, or \n        retailers of the drug)--\n                    ``(A) to immediately cease distribution of the \n                drug; and\n                    ``(B) to immediately notify health professionals of \n                the order and to instruct such professionals to cease \n                administering or prescribing the drug.\n            ``(2) Informal hearing.--An order under paragraph (1) shall \n        provide the person subject to the order with an opportunity for \n        an informal hearing, to be held not later than 10 days after \n        the date of the issuance of the order, on the actions required \n        by the order and on whether the order should be amended to \n        require a recall of the drug involved. If, after providing an \n        opportunity for such a hearing, the Secretary determines that \n        inadequate grounds exist to support the actions required by the \n        order, the Secretary shall vacate the order.\n    ``(b) Order To Recall Drug.--\n            ``(1) In general.--If, after providing an opportunity for \n        an informal hearing under subsection (a)(2), the Secretary \n        determines that the order should be amended to include a recall \n        of the drug with respect to which the order was issued, the \n        Secretary shall, except as provided in paragraphs (2) and (3), \n        amend the order to require a recall. The Secretary shall \n        specify a timetable in which the drug recall will occur and \n        shall require periodic reports to the Secretary describing the \n        progress of the recall.\n            ``(2) Certain actions.--An amended order under paragraph \n        (1)--\n                    ``(A) shall not include recall of a drug from \n                individuals; and\n                    ``(B) shall provide for notice to individuals \n                subject to the risks associated with the use of the \n                drug.\n            ``(3) Assistance of health professionals.--In providing the \n        notice required by paragraph (2)(B), the Secretary may use the \n        assistance of health professionals who administered the drug \n        involved to individuals or prescribed the drug for individuals. \n        If a significant number of such individuals cannot be \n        identified, the Secretary shall notify such individuals \n        pursuant to section 705(b).''.\n\nSEC. 8. AUTHORITY TO ISSUE SUBPOENAS WITH RESPECT TO PREVENTING THREATS \n              TO THE PUBLIC HEALTH.\n\n    Section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n333) is amended by adding at the end the following subsection:\n    ``(g) The Secretary and the Attorney General shall develop and \nimplement a procedure through which the Chief Counsel in the Food and \nDrug Administration is authorized to issue subpoenas regarding \ninvestigations under this Act of acts or omissions that may constitute \na threat to the public health, including investigations of alleged \nviolations to which paragraph (3) or (4) of subsection (a) apply and \nalleged violations with respect to which the Secretary is considering \nthe use of authorities under section 304.''."
}